4D Molecular Therapeutics Announces First Patients Enrolled In Phase 3 Trial Of 4D-150 In Diabetic Macular Edema; 2-Year Data Show 61% Fewer Injections

Loading news article.

4D Molecular Therapeutics Announces First Patients Enrolled In Phase 3 Trial Of 4D-150 In Diabetic Macular Edema; 2-Year Data Show 61% Fewer Injections | WAPE

4D Molecular Therapeutics Announces First Patients Enrolled In Phase 3 Trial Of 4D-150 In Diabetic Macular Edema; 2-Year Data Show 61% Fewer Injections

Article summary

Related companies

Comments —